Sign Up for Alerts
Sign up to receive receive industry-specific emails from our legal team.
Sign Up for Alerts
We provide tailored, industry-specific legal updates to our clients and other friends of the firm.
Areas of Interest
December 15th, 2022
AdExplainer: Your CPRA Download
Privacy & Data Security Chair Daniel M. Goldberg is quoted in the article, “AdExplainer: Your CPRA Download” published by AdExchanger. The article details the CPRA, an amendment that expands and updates the California Consumer Privacy Act (CCPA). Part of CPRA compliance is implementing the Global Privacy Control (GPC), a universal browser-based mechanism that lets users opt out of their information being shared or sold across sites and sends that signal to publishers, advertisers and third-party companies. Daniel is quoted saying, “Companies are struggling with implementation. We just have to wait to see where the market goes. But, right now, it’s clear that GPC is the de facto recognized signal, and it needs to be addressed.”
Read the full article here.
Other Quoted
Climate Diaries Cannes Lions 2026
Jeffrey A. Greenbaum is featured in the 51toCarbonZero article, Climate Diaries Cannes Lions 2026, which features eleven interviews with senior leaders from across the media and advertising industry conducted at the Cannes Lions International Festival of Creativity. Read more.
August 5 2026
‘I have been hunted down by HR reps, lawyers, and comms people:’ Developers discuss the pain and prevalence of side work clauses
Wendy Stryker was quoted in a Game Developer article discussing "side work clauses," also known as "moonlighting clauses," in video game industry employment contracts. Read more.
July 30 2026
Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads
Jeffrey A. Greenbaum was quoted in the Regulatory Affairs Professionals Society (RAPS) article, "Experts: Ending Adequate Provision Would Shut Down Prescription Drug Ads." The article discusses the FDA's proposal to eliminate the "adequate provision" requirement in direct-to-consumer (DTC) prescription drug advertising, a change that experts say could effectively result in a de facto ban on prescription drug advertisements. Read more.
July 21 2026
